LL-37

Overview

LL-37 is the only cathelicidin-family antimicrobial peptide produced in humans — a 37-residue cationic, amphipathic peptide cleaved from the precursor hCAP18 (the CAMP gene product). It is made by neutrophils and epithelial cells as a frontline part of innate immunity, and beyond killing microbes it strongly modulates inflammation, wound repair and angiogenesis. It is best understood as a "double-edged" molecule: protective in host defense but mechanistically tied to autoimmune and inflammatory disease when dysregulated. There is no FDA-approved LL-37 therapeutic; it is research-only and has reached the clinic only as a topical wound agent.

Mechanism

LL-37 acts two ways. Its cationic, amphipathic structure binds anionic microbial membranes and disrupts them, giving broad antimicrobial and anti-biofilm activity. Second, it is a potent immunomodulator, engaging host receptors — notably FPR2 and scavenger receptors (SR-B1, LOX-1, RAGE) — to influence chemotaxis, cytokines, angiogenesis and proliferation. Critically, it binds host nucleic acids: LL-37–self-DNA complexes activate TLR9 in plasmacytoid dendritic cells (driving type-I interferon), the pathway that links it to psoriasis and lupus. Much of this receptor-level detail comes from in-vitro human-cell work, not whole-organism studies.

Clinical evidence

Human therapeutic data are limited to topical wound healing. A first-in-human phase I/II trial in hard-to-heal venous leg ulcers (Grönberg et al., 2014; n=34) reported that low-dose topical LL-37 produced healing-rate constants several-fold higher than placebo, while the highest dose offered no benefit — a biphasic, concentration-dependent effect. However, the larger phase IIb trial (Mahlapuu et al., 2021; n=148) did not meet its primary endpoint, with a positive signal only in a post-hoc subgroup of large wounds. Everything else — antimicrobial, anticancer and broad immunomodulatory work — is in-vitro or preclinical. LL-37 is not approved for any indication.

Safety profile

LL-37 is not a benign molecule. In vitro it shows clear concentration-dependent cytotoxicity and hemolysis of host cells above the antimicrobial range, and it is mechanistically implicated in driving autoimmune/inflammatory disease (psoriasis, lupus, rosacea); experimental work shows it can activate platelets and promote thrombus formation. Against this, the topical venous-ulcer trials reported good local and systemic tolerability with only mild application-site reactions. Net: tolerable in controlled low-dose topical use, but systemic research-grade exposure carries real, biology-driven risks and is not established as safe. Research-use only; FDA-not-evaluated.

Compare

• vs Thymosin Alpha-1

  Another immune-active peptide, but Ta1 is an approved-abroad immunomodulator with substantial human trial data, whereas LL-37 is a host-defense peptide with a double-edged, partly pro-inflammatory profile.

• vs KPV

  KPV is a short anti-inflammatory tripeptide explored for similar repair/anti-inflammatory contexts, but without LL-37's cytotoxicity and autoimmune-driving liabilities.